TWI889738B - 於c-17具有基於氮之取代基的合成之三萜系化合物以及其使用方法 - Google Patents

於c-17具有基於氮之取代基的合成之三萜系化合物以及其使用方法

Info

Publication number
TWI889738B
TWI889738B TW109145170A TW109145170A TWI889738B TW I889738 B TWI889738 B TW I889738B TW 109145170 A TW109145170 A TW 109145170A TW 109145170 A TW109145170 A TW 109145170A TW I889738 B TWI889738 B TW I889738B
Authority
TW
Taiwan
Prior art keywords
compound
substituted
mmol
pharmaceutically acceptable
tautomer
Prior art date
Application number
TW109145170A
Other languages
English (en)
Chinese (zh)
Other versions
TW202135828A (zh
Inventor
克里斯多福 Ｆ 班德
夏 都
江昕
孫海洲
米蓮恩 維斯尼克
英戈 詹瑟
羅伊 Ｊ 賽門斯
海因利奇 Ｊ 休斯塔雷
Original Assignee
美商瑞塔醫藥有限責任公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商瑞塔醫藥有限責任公司 filed Critical 美商瑞塔醫藥有限責任公司
Publication of TW202135828A publication Critical patent/TW202135828A/zh
Application granted granted Critical
Publication of TWI889738B publication Critical patent/TWI889738B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
TW109145170A 2019-12-19 2020-12-18 於c-17具有基於氮之取代基的合成之三萜系化合物以及其使用方法 TWI889738B (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201962950927P 2019-12-19 2019-12-19
US201962950919P 2019-12-19 2019-12-19
US62/950,919 2019-12-19
US62/950,927 2019-12-19
US202063198310P 2020-10-09 2020-10-09
US63/198,310 2020-10-09

Publications (2)

Publication Number Publication Date
TW202135828A TW202135828A (zh) 2021-10-01
TWI889738B true TWI889738B (zh) 2025-07-11

Family

ID=74554207

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109145170A TWI889738B (zh) 2019-12-19 2020-12-18 於c-17具有基於氮之取代基的合成之三萜系化合物以及其使用方法

Country Status (20)

Country Link
US (1) US20230111914A1 (https=)
EP (1) EP4077347A1 (https=)
JP (1) JP2023507402A (https=)
KR (1) KR20220116209A (https=)
CN (1) CN115087660A (https=)
AU (1) AU2020405181A1 (https=)
BR (1) BR112022011919A2 (https=)
CA (1) CA3159778A1 (https=)
CL (1) CL2022001661A1 (https=)
CO (1) CO2022010070A2 (https=)
CR (1) CR20220345A (https=)
DO (1) DOP2022000127A (https=)
EC (1) ECSP22055210A (https=)
IL (1) IL293876B2 (https=)
MX (1) MX2022007595A (https=)
PE (1) PE20221662A1 (https=)
PH (1) PH12022551493A1 (https=)
SA (1) SA522432999B1 (https=)
TW (1) TWI889738B (https=)
WO (1) WO2021127480A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5529851B2 (ja) 2008-04-18 2014-06-25 リアタ ファーマシューティカルズ インコーポレイテッド 抗酸化炎症モジュレーター：ｃ−１７においてアミノ改変およびその他の改変を加えたオレアノール酸誘導体
JP7074674B2 (ja) 2015-09-23 2022-05-24 リアタ ファーマシューティカルズ インコーポレイテッド Ｉｌ－１７の阻害及び他の使用のためのｃ４修飾オレアノール酸誘導体
AU2021397631A1 (en) * 2020-12-11 2023-07-20 Reata Pharmaceuticals Holdings, LLC Synthetic triterpenoids for use in therapy
CN117964678A (zh) * 2024-01-29 2024-05-03 烟台大学 C17位杂芳族羰基修饰的齐墩果烷三萜衍生物及其制备方法和用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009129548A1 (en) * 2008-04-18 2009-10-22 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: c-17 homologated oleanolic acid derivatives
WO2009129546A1 (en) * 2008-04-18 2009-10-22 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17
US20110245233A1 (en) * 2008-04-18 2011-10-06 Eric Anderson Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the c-ring

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR096046A1 (es) * 2013-04-24 2015-12-02 Abbvie Inc Derivados de 2,2-difluoropropanamida de metil bardoxolona, formas polimórficas y métodos de uso
MX2021003643A (es) * 2018-09-28 2021-08-19 Sichuan Haisco Pharmaceutical Co Ltd Derivados de terpenoides y usos de los mismos.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009129548A1 (en) * 2008-04-18 2009-10-22 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: c-17 homologated oleanolic acid derivatives
WO2009129546A1 (en) * 2008-04-18 2009-10-22 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17
US20110245233A1 (en) * 2008-04-18 2011-10-06 Eric Anderson Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the c-ring

Also Published As

Publication number Publication date
IL293876B2 (en) 2026-03-01
US20230111914A1 (en) 2023-04-13
CO2022010070A2 (es) 2022-08-09
PH12022551493A1 (en) 2023-11-13
IL293876A (en) 2022-08-01
IL293876B1 (en) 2025-11-01
TW202135828A (zh) 2021-10-01
MX2022007595A (es) 2022-07-19
SA522432999B1 (ar) 2025-04-10
CA3159778A1 (en) 2021-06-24
BR112022011919A2 (pt) 2022-09-06
CN115087660A (zh) 2022-09-20
PE20221662A1 (es) 2022-10-26
KR20220116209A (ko) 2022-08-22
DOP2022000127A (es) 2022-09-15
CL2022001661A1 (es) 2023-01-27
ECSP22055210A (es) 2022-08-31
AU2020405181A1 (en) 2022-07-14
JP2023507402A (ja) 2023-02-22
EP4077347A1 (en) 2022-10-26
WO2021127480A1 (en) 2021-06-24
CR20220345A (es) 2023-01-12

Similar Documents

Publication Publication Date Title
TWI889738B (zh) 於c-17具有基於氮之取代基的合成之三萜系化合物以及其使用方法
DK2651902T3 (en) TRICYCLIC PYRAZOLYL AND PYRIMIDINYL ENONES AS ANTIOXIDANT INFLAMMATION MODULATORS
US20250361263A1 (en) C17 polar-substituted heteroaromatic synthetic triterpenoids and methods of use thereof
EP3353190A1 (en) C4-modified oleanolic acid derivatives for inhibition of il-17 and other uses
CA2974726C (en) Imidazolyl tricyclic enones as antioxidant inflammation modulators
EP4277916A1 (en) Synthetic ursolic acid derivatives and methods of use thereof
EA049347B1 (ru) Синтетические тритерпеноиды с заместителями на основе азота у атома c-17 и способы их применения
HK40080975A (en) Synthetic triterpenoids with nitrogen-based substituents at c-17 and methods of use thereof
HK40073498A (en) C17 polar-substituted heteroaromatic synthetic triterpenoids and methods of use thereof
HK40073498B (zh) C17极性的-取代的杂芳族合成三萜类化合物及其使用方法
HK40101927A (zh) 合成的熊果酸衍生物和其使用方法